AMH Equity Ltd Acquires 25,000 Shares of OptimizeRx Co. (NASDAQ:OPRX)

AMH Equity Ltd lifted its holdings in shares of OptimizeRx Co. (NASDAQ:OPRX) by 25.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 125,000 shares of the company’s stock after purchasing an additional 25,000 shares during the period. AMH Equity Ltd owned 0.68% of OptimizeRx worth $608,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Rice Hall James & Associates LLC lifted its holdings in OptimizeRx by 24.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock worth $4,751,000 after buying an additional 119,306 shares during the period. Janney Montgomery Scott LLC bought a new position in shares of OptimizeRx during the third quarter worth about $810,000. Bullseye Asset Management LLC lifted its stake in shares of OptimizeRx by 55.6% in the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock worth $1,652,000 after acquiring an additional 76,458 shares during the period. Greenwood Capital Associates LLC boosted its holdings in OptimizeRx by 31.5% in the fourth quarter. Greenwood Capital Associates LLC now owns 88,596 shares of the company’s stock valued at $431,000 after acquiring an additional 21,240 shares during the last quarter. Finally, Barclays PLC increased its position in OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after purchasing an additional 21,060 shares during the period. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Price Performance

Shares of NASDAQ OPRX opened at $5.11 on Thursday. The firm has a market capitalization of $94.13 million, a P/E ratio of -3.84 and a beta of 1.38. The firm’s 50-day moving average price is $5.44 and its 200-day moving average price is $6.17. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx Co. has a 1-year low of $3.78 and a 1-year high of $16.65.

Insider Activity at OptimizeRx

In other news, CEO William J. Febbo purchased 20,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the acquisition, the chief executive officer now owns 601,253 shares in the company, valued at approximately $3,012,277.53. The trade was a 3.44 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

OPRX has been the topic of a number of recent analyst reports. JMP Securities restated a “market outperform” rating and issued a $8.00 price target on shares of OptimizeRx in a research report on Thursday, February 6th. Barclays dropped their target price on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, November 14th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. William Blair reissued an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Finally, B. Riley cut their target price on OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, December 24th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.06.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.